SCHEMBL7797970

SCHEMBL7797970

CCOc1cc(OC)c(C(=O)Nc2cccc3c2CCN(C)C3)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.42
MEN1 O00255 6/20 0.42
MAP4K1 Q92918 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAP3K5 Q99683 1/20 0.40
MAPT P10636 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
NR4A1 P22736 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7802393 0.95 KMT2A (0.44) KMT2AMEN1MAP4K1SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL7797935 0.94 KMT2A (0.43) KMT2AMEN1MAP4K1SMN1; SMN2MAPK1
SCHEMBL8184618 0.93 KMT2A (0.46) KMT2AMEN1SIGMAR1SMN1; SMN2USP2
SCHEMBL7797917 0.90 SIGMAR1 (0.44) KMT2AMEN1SIGMAR1
SCHEMBL7797950 0.89 KDM4E (0.44) KMT2AMEN1MAP4K1SMN1; SMN2MAPK1
SCHEMBL8183726 0.89 KMT2A (0.44) KMT2AMEN1MAP4K1SMN1; SMN2USP2
SCHEMBL8184203 0.89 KMT2A (0.42) KMT2AMEN1MAP4K1SIGMAR1SMN1; SMN2
SCHEMBL7797946 0.88 KMT2A (0.43) KMT2AMEN1MAP4K1SMN1; SMN2MAPK1
SCHEMBL7791958 0.88 MEN1 (0.43) KMT2AMEN1MAP4K1SMN1; SMN2L3MBTL1
SCHEMBL8176110 0.87 MAP3K5 (0.43) KMT2AMEN1MAP4K1SIGMAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A KMT2A 445/4885MEN1 3408/4885MAP4K1 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.